Proteomics research towards personalized treatments for cancer, diabetes and inflammatory diseases

Current article ratings:
Patients / public:healthcare Prof:
NeoProteomics Inc., a biomarker development and software company, has an exclusive option agreement with case Western Reserve University secured. The business has potential to improve the various forms of treatment of cancer, diabetes and inflammatory diseases.

Proteomics is the scientific next step in the vital research of protein structure of biological systems. NeoProteomics, founded in the year 2006 in Cleveland in the vicinity of case Western Reserve's School of medicine, focuses on biomarker discovery and validation and tried, that the development of unique and improved analysis tools spearhead.

Mark R. chance, PhD, NeoProteomics co-founder and chief scientific officer, said the exclusive option, founded by case Western Reserve transfer Office, technology will contribute significantly to tools and enable biomarkers, which the company expand its portfolio in the growing field of personalized medicine.

"In particular, be they help milestones in clinical trials for the drug speed and companion development of major pharmaceutical companies provide diagnosis," said chance. Chance is Director, case Center for Proteomics and bioinformatics. Professor, Department of General Medical Sciences; Director, event Centre for synchrotron Biosciences and Professor and interim of Chairman of the Department of Genetics at the University's School of medicine.

Agreement option reserves the right to the intellectual property for the company and was negotiated by Michael Haag, Director of the bio-medical licensing for case Western Reserve.

"NeoProteomics has developed an exciting business model, the software business, which they call their 'innovation engine', directly in flow can, and drive business be biomarkers,", Hague said. "We are proud to partner with NeoProteomics, and look forward to a long relationship."

NeoProteomics contains also John L. H. thighs Jr., co-founder, President and CEO, and Steven chance, JD, Secretary and general counsel. Proteomics specialist Rod Nibbe, PhD, has joined the management team as a research associate and Manager of product development recently.

Recently, the company received a grant from the Innovation Fund, founded by the Lorain County Community College Foundation. The grant to and continue to develop the business models develop laboratory tests to validate who said clinical significance, biomarker thighs.

Thighs confirms the support and feedback from the Great Lakes GLIDE (innovation development enterprise), the financing to help developing biomarkers licensed from the University.

Currently, NeoProteomics software is already licensed by case Western Reserve distribute. The software, ProtMapMS, accelerated structural biology research by mass spectrometry workflow automation. It has large pharmaceutical companies and some of the most prestigious research universities in the country licensed.

Additional bioinformatics software solutions from NeoProteomics, also based on case Western Reserve technologies, to high-throughput genomics and proteomics data integrated into the clinical research and are under development.

"We want to build a platform of new software products, which will increase the speed on the academic, who and pharmaceutical researchers of their clinical and translational work do," said thighs.

Source:
Marv Kropko
Case Western Reserve University